Key Points
- Director Bart Filius bought 150,000 ProQR Therapeutics shares at an average $1.72 each, investing $258,000 and doubling his direct ownership to 300,000 shares. He also purchased 150,000 shares in June.
- ProQR shares opened at $1.76 and have traded between $1.33 and $3.10 over the past year. The company reported a quarterly loss of $0.15 per share, in line with estimates, but revenue of $2.35 million fell short of the $5.19 million forecast.
- Analyst sentiment remains mixed but leans positive, with an overall “Moderate Buy” rating and a consensus price target of $7.33; institutional investors own 32.65% of the company.
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Bart Filius also recently made the following trade(s):
- On Friday, June 26th, Bart Filius bought 150,000 shares of ProQR Therapeutics stock. The shares were bought at an average cost of $1.54 per share, with a total value of $231,000.00.
ProQR Therapeutics Trading Up 1.7%
NASDAQ PRQR opened at $1.76 on Wednesday. The stock has a market cap of $185.43 million, a PE ratio of -3.52 and a beta of 0.04. ProQR Therapeutics N.V. has a 12 month low of $1.33 and a 12 month high of $3.10. The company's 50-day moving average price is $1.66 and its 200-day moving average price is $1.65.
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15). The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, sell-side analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.
Wall Street Analyst Weigh In
PRQR has been the subject of a number of research reports. Citigroup reiterated a "market outperform" rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Chardan Capital decreased their target price on ProQR Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, June 26th. Wall Street Zen lowered ProQR Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. JonesTrading lowered their target price on ProQR Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday, June 26th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, ProQR Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $7.33.
View Our Latest Stock Report on ProQR Therapeutics
Hedge Funds Weigh In On ProQR Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its position in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 4,500 shares during the last quarter. Guggenheim Capital LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $35,000. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $50,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $51,000. Finally, Axiom Investment Management LLC purchased a new position in ProQR Therapeutics in the first quarter worth $53,000. Hedge funds and other institutional investors own 32.65% of the company's stock.
ProQR Therapeutics Company Profile
(
Get Free Report)
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
